focus -WSS

focus

author：entertainment 2025-08-06 05:21:35 - browse：39532

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

MD Anderson's Padmanee Sharma responds to research credit suit

Reporting on presidential health from Reagan to Trump and Biden

Harvard scientists, with Google, unveil the most detailed brain map ever

Medicare Advantage enrollment hits roughly 33.4 million

Trial using CRISPR to edit HIV out of cells disappoints

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

Gut bacteria may contribute to kidney autoimmunity, study finds

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Weight loss drugs aren’t covered by Obamacare. That may change

How one medical school became remarkably diverse

FDA warns medical device makers about rise in fabricated data

Novavax promises a turnaround & Lilly roils the obesity market

Gut bacteria may contribute to kidney autoimmunity, study finds

Tori Bowie and the unacceptable rates of Black maternal death

As AI regulations shape up, health tech startups beg for clarity

entertainment

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Pancreatic cancer is often deadly, but new discoveries are raising hope

Researchers tackle phage therapy hurdles for wider adoption

Republican states more likely to report Covid vaccine side effects

Mass General Brigham physicians react to latest merger step

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

knowledge

knowledge

knowledge

explore